Biomarker & Intervention Discovery
Sickle Cell Disease
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs46.6KWHO GHE 2021 · all ages
Global DALYs4.74MWHO GHE 2021 · worldwide
US mortality720 deaths/yrWHO GHE 2021
Global mortality33.3K deaths/yrWHO GHE 2021 · worldwide
NIH funding$155MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionNo spontaneous remission; progressive organ damage; median survival historically 40-60 years but improving…
Best-intervention remissionHaematopoietic stem cell transplant (HSCT): curative in 90-95% if matched sibling donor available; hydroxyurea reduces…
Gap sizeVery large — HSCT is curative but only 20% have matched donors; gene therapy is curative but costs $2-3M; hydroxyurea…
Primary barrieraccess
Full remission profile →
Remission & chronicity
Spontaneous remission
No spontaneous remission; progressive organ damage; median survival historically 40-60 years but improving; vaso-occlusive crises (VOC) in 1-4 per year average
Best-intervention remission
Haematopoietic stem cell transplant (HSCT): curative in 90-95% if matched sibling donor available; hydroxyurea reduces VOC frequency 50%, ACS risk 50%; gene therapy (exagamglogene autotemcel [exa-cel]/Casgevy): 30/31 patients free from severe VOC through 24 months; betibeglogene (Zynteglo): 90% reduction in severe VOC
Gap size
Very large — HSCT is curative but only 20% have matched donors; gene therapy is curative but costs $2-3M; hydroxyurea is dramatically underprescribed
Hydroxyurea is inexpensive, highly effective, and generic but prescribed to only 25-35% of eligible SCD patients (racial and healthcare access disparities prominent); gene therapies (Casgevy, Zynteglo) approved December 2023 represent first curative options without matched donor — but $2-3M price tag makes access essentially impossible without negotiation
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Sickle Cell Disease” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."